Mga Batayang Estadistika
| CIK | 1399250 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Transition Therapeutics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 13, 2016 |
Transition Therapeutics 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-33514 Transition Therapeutics Inc. (Exact name of registrant as specifi |
|
| September 13, 2016 |
Transition Therapeutics S-8 POS As filed with the Securities and Exchange Commission on September 13, 2016 Registration No. |
|
| September 9, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by ch |
|
| September 9, 2016 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.1 2 v448583ex99-1.htm MATERIAL CHANGE REPORT FILED SEPTEMBER 9, 2016. Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Transition Therapeutics Inc. (“Transition”) Suite 220 – 101 College Street Toronto, ON M5G 1L7 Item 2: Date of Material Change August 31, 2016 Item 3: News Release A news release announcing the material change was disseminated on August 3 |
|
| August 31, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| August 26, 2016 |
EX-99.1 2 v447747ex99-1.htm PRESS RELEASE DATED AUGUST 25, 2016 Exhibit 99.1 Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc. TORONTO, ON, August 25, 2016 – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) is pleased to announce that the Company has rece |
|
| August 26, 2016 |
EX-99.1 2 v447747ex99-1.htm PRESS RELEASE DATED AUGUST 25, 2016 Exhibit 99.1 Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc. TORONTO, ON, August 25, 2016 – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) is pleased to announce that the Company has rece |
|
| August 26, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| August 26, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| August 4, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| August 4, 2016 |
EX-99.1 2 v445986ex99-1.htm NOTICE OF SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS to be held August 25, 2016 and NOTICE OF APPLICATION TO THE ONTARIO SUPERIOR COURT OF JUSTICE (COMMERCIAL LIST) and INFORMATION CIRCULAR and PROXY STATEMENT with respect to a PROPOSED PLAN OF ARRANGEMENT involving TRANSITION THERAPEUTICS INC. and OPKO HEALTH, INC. and OPKO G |
|
| July 13, 2016 |
EX-99.1 2 v444207ex99-1.htm NOTICE OF SPECIAL MEETING Exhibit 99.1 Date: July 13, 2016 100 University Avenue, 8th floor Toronto ON, M5J 2Y1 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: TRANSITION THERAPEUTICS INC Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Special Mee |
|
| July 13, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| July 6, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4437926k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executiv |
|
| July 6, 2016 |
EX-99.1 2 v443792ex99-1.htm MATERIAL CHANGE REPORT DATED JULY 6, 2016 Exhibit 99.1 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer: Transition Therapeutics Inc. (“Transition”) 101 College Street, Suite 220 Toronto, Ontario M5G 1L7 Item 2. Date of Material Change: June 29, 2016 Item 3. News Release: A joint news release disclosing the material change described below was issued b |
|
| June 30, 2016 |
Transition Therapeutics 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| June 30, 2016 |
OPKO Health to Acquire Transition Therapeutics Exhibit 99.1 OPKO Health to Acquire Transition Therapeutics ? All-stock transaction valued at approximately US$60 million, or US$1.55 per Transition Therapeutics share ? OPKO to gain potential first-to-market GLP-1/Glucagon dual agonist for type 2 diabetes and obesity and phase 2 drug candidate for the treatment of androgen deficiency MIAMI and TORONTO (June 30, 2016) ? OPKO Health, Inc. (NASDAQ: |
|
| June 3, 2016 |
Transition Therapeutics Receives Notification From NASDAQ EX-99.1 2 ex991.htm NEWS RELEASE DATED JUNE 3, 2016 Exhibit 99.1 Transition Therapeutics Receives Notification From NASDAQ TORONTO, June 3, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced that it received written notification from the NASDAQ Stock Market ("NASDAQ") on May 31, 2016 advising the Company that because the bid price of |
|
| June 3, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| May 11, 2016 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE EX-99.5 6 v439356ex99-5.htm CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF FINANCIAL OFFICER Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therap |
|
| May 11, 2016 |
Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results EX-99.1 2 v439356ex99-1.htm PRESS RELEASE DATED MAY 11, 2016 Exhibit 99.1 Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results TORONTO, ON, May 11, 2016 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS, metabolic disease and androgen deficiency indications, |
|
| May 11, 2016 |
EX-99.3 4 v439356ex99-3.htm CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.3 Consolidated Interim Financial Statements (Unaudited) Transition Therapeutics Inc. For the nine and three months ended March 31, 2016 and 2015 Transition Therapeutics Inc. CONSOLIDATED BALANCE SHEETS (Unaudited) In Canadian Dollars Note As At March 31, 2016 As at June 30, 2015 Assets Current assets Cash 24,768,772 40,510,75 |
|
| May 11, 2016 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE EX-99.4 5 v439356ex99-4.htm CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF EXECUTIVE OFFICER Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeut |
|
| May 11, 2016 |
EX-99.6 7 v439356ex99-6.htm LETTER TO SHAREHOLDERS Exhibit 99.6 To Our Shareholders, Fiscal Q3 2016 is highlighted by the announcement of top-line results from our diabetes drug candidate TT401. In parallel, the Company has commenced an interaction with the FDA to assess the future development plan for the ELND005 program. Subsequent to the quarter end, the Company also announced the start of the |
|
| May 11, 2016 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company?s unaudited consolidated financial statements for the three and nine month periods ended March 31, 2016 and the related notes, which are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board for interi |
|
| May 11, 2016 |
Transition Therapeutics 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 9, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 9, 2016 |
EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 9, 2016 Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST TORONTO, May 9, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 11th, 2016 at 4:30 P.M. EST to discuss |
|
| April 26, 2016 |
Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 Exhibit 99.1 Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 TORONTO, April 25, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient of a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate TT701. The Phase 2 study will evaluate t |
|
| April 26, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| April 18, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| April 18, 2016 |
Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401 EX-99.1 2 ex991.htm NEWS RELEASE DATED APRIL 18, 2016 Exhibit 99.1 Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401 TORONTO, April 18, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced that it has received notification that Eli Lilly and Co. ("Lilly") will not elect to advance diabetes drug candidate, T |
|
| March 24, 2016 |
Transition Therapeutics Receives Notification From NASDAQ EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 17, 2016 Exhibit 99.1 Transition Therapeutics Receives Notification From NASDAQ TORONTO, March 17, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced that it received written notification from The NASDAQ Stock Market ("NASDAQ") on March 15, 2016 advising the Company that because the bid pri |
|
| March 24, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| March 1, 2016 |
Transition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 1, 2016 Exhibit 99.1 Transition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference TORONTO, March 1, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Cowen Healthcare Confe |
|
| March 1, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| February 11, 2016 |
CUSIP No. 893716209 EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement is entered into as of February 11, 2016, by the undersigned, who hereby agree that the Statement on Amendment No. 3 to Schedule 13D in respect of the common shares of Transition Therapeutics Inc. is filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| February 11, 2016 |
TTHI / Transition Therapeutics Inc. / SCHULER JACK W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) TRANSITION THERAPEUTICS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 893716209 (CUSIP Number) Jack W. Schuler c/o Crabtree Partners LLC 100 N. Field Drive, #360 Lake Forest, Illinois 60045 (224) 880-1211 (Name, Address and Telephone |
|
| February 9, 2016 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company?s unaudited consolidated financial statements for the three and six month periods ended December 31, 2015 and the related notes, which are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board for inte |
|
| February 9, 2016 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Transition Therapeutics Inc. (the ?issuer?) for the interim period ended December 31, 2015. 2. No misrepresentations: B |
|
| February 9, 2016 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE EX-99.5 6 v430769ex99-5.htm CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF FINANCIAL OFFICER Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therap |
|
| February 9, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 9, 2016 |
Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results Exhibit 99.1 Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results TORONTO, ON, February 9, 2016 ? Transition Therapeutics Inc. (?Transition? or the ?Company?) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three and six month periods end |
|
| February 9, 2016 |
Consolidated Financial Statements EX-99.3 4 v430769ex99-3.htm CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.3 Consolidated Financial Statements (Unaudited) Transition Therapeutics Inc. For the three and six months ended December 31, 2015 and 2014 Transition Therapeutics Inc. CONSOLIDATED BALANCE SHEETS (Unaudited) In Canadian Dollars Note As At December 31, 2015 As at June 30, 2015 Assets Current assets Cash 29,070,189 40,510,758 O |
|
| February 9, 2016 |
EX-99.6 7 v430769ex99-6.htm LETTER TO SHAREHOLDERS Exhibit 99.6 To Our Shareholders In the second quarter of fiscal 2016 and shortly thereafter, the Company announced important findings that will guide the future of its two lead development programs. For ELND005, the Company held an Investor Day in November to provide an update on the analysis of the Phase 2/3 study completed in June 2015. This up |
|
| February 5, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 5, 2016 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST TORONTO, Feb. 5, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, February 9th, 2016 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2016 financial results. |
|
| February 3, 2016 |
TTHI / Transition Therapeutics Inc. / FEINBERG LARRY N - SCHEDULE 13G/A, #9 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 9) Under the Securities Exchange Act of 1934 Transition Therapeutics, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 893716209 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 1, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 1, 2016 |
Exhibit 99.1 Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401 TORONTO, Feb. 1, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the results of a Phase 2 clinical study of drug candidate TT401 (LY2944876) for the treatment of type 2 diabetes. TT401 is a once-weekly administere |
|
| January 19, 2016 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2016 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by chec |
|
| January 19, 2016 |
Transition Therapeutics Announces Annual General Meeting Voting Results Exhibit 99.1 Transition Therapeutics Announces Annual General Meeting Voting Results TORONTO, Jan. 6, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announces that the following five directors were elected at the Annual General Meeting of shareholders of the Company held on December 10, 2015 (the "Meeting"): NOMINEE VOTES IN FAVOR % VOTES WITHHEL |
|
| December 11, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| December 11, 2015 |
Exhibit 99.1 TRANSITION THERAPEUTICS INC. ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON DECEMBER 10, 2015 PREPARED BY COMPUTERSHARE INVESTOR SERVICES INC. TORONTO TRANSITION THERAPEUTICS INC. ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON DECEMBER 10, 2015 FINAL SCRUTINEERS' REPORT 2 SHAREHOLDERS IN PERSON, REPRESENTING 15,822 SHARES 67 SHAREHOLDERS BY PROXY, REPRESENTING 30,988,319 SHARES 69 TOT |
|
| November 19, 2015 |
TRANSITION THERAPEUTICS INC. Annual Meeting of Shareholders Management Information Circular Exhibit 99.1 TRANSITION THERAPEUTICS INC. Annual Meeting of Shareholders Management Information Circular This Management Information Circular (?Circular?) is furnished in connection with the solicitation of proxies by and on behalf of the management of Transition Therapeutics Inc. (the ?Corporation?) for use at the Annual Meeting of the Corporation?s shareholders to be held on December 10, 2015 at |
|
| November 19, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 19, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 19, 2015 |
Live Webcast Beginning at 12 PM Eastern Time Exhibit 99.1 Transition Therapeutics to Host Investor Day November 23 in New York Live Webcast Beginning at 12 PM Eastern Time TORONTO, Nov. 19, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that it will host an Investor Day on Monday, November 23rd in New York City. An industry key opinion leader, Jacobo Mintzer, MD, and Transit |
|
| November 19, 2015 |
Exhibit 99.2 |
|
| November 10, 2015 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE EX-99.4 5 v424095ex99-4.htm CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF EXECUTIVE OFFICER Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeut |
|
| November 10, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company?s unaudited consolidated financial statements for the three-month period ended September 30, 2015 and the related notes, which are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board for interim fina |
|
| November 10, 2015 |
Exhibit 99.3 Consolidated Financial Statements (Unaudited) Transition Therapeutics Inc. For the three months ended September 30, 2015 and 2014 Transition Therapeutics Inc. CONSOLIDATED BALANCE SHEETS (Unaudited) In Canadian Dollars Note As At September 30, 2015 As at June 30, 2015 Assets Current assets Cash 31,803,201 40,510,758 Other receivables 330,160 265,189 Income tax and investment tax credi |
|
| November 10, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 10, 2015 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Transition Therapeutics Inc. (the ?issuer?) for the interim period ended September 30, 2015. 2. No misrepresentation |
|
| November 10, 2015 |
Exhibit 99.6 To Our Shareholders, The first quarter of fiscal 2015 is highlighted by the completion of the data analysis from the ELND005 Phase 2/3 study, Lilly?s advancement of the TT401 study and the progress of TT701 toward commencing a Phase 2 study. Neuropsychiatric Drug Candidate ELND005 Subsequent to the quarter-end, Transition?s subsidiary Transition Therapeutics Ireland Limited (?TTIL?) c |
|
| November 10, 2015 |
Transition Therapeutics Announces First Quarter Fiscal 2016 Financial Results Exhibit 99.1 Transition Therapeutics Announces First Quarter Fiscal 2016 Financial Results TORONTO, ON, November 10, 2015 ? Transition Therapeutics Inc. (?Transition? or the ?Company?) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three month period ended Septem |
|
| November 4, 2015 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2016 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST TORONTO, Nov. 2, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, November 10th, 2015 at 4:30 P.M. EST to discuss First Quarter Fiscal 2016 financial results. |
|
| November 4, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| October 29, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by chec |
|
| October 29, 2015 |
Transition Therapeutics Announces Agreement for Phase 2 Study of TT701 Drug Candidate Exhibit 99.1 Transition Therapeutics Announces Agreement for Phase 2 Study of TT701 Drug Candidate TORONTO, Oct. 29, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Transition Therapeutics Ireland Limited ("TTIL") has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Wo |
|
| October 28, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by chec |
|
| October 28, 2015 |
Exhibit 99.1 Transition Therapeutics Announces Presentation of ELND005 Phase 2/3 Clinical Study Results at Clinical Trials in Alzheimer's Disease (CTAD) Conference TORONTO, Oct. 28, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that data from the Phase 2/3 clinical study of ELND005 in Alzheimer's disease patients with moderate an |
|
| October 15, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by chec |
|
| October 15, 2015 |
Exhibit 99.1 Transition Therapeutics Announces Results of Data Analysis from ELND005 Phase 2/3 Clinical Study in Agitation and Aggression in Alzheimer's Disease Patients Primary efficacy endpoint not achieved in overall study ELND005 significantly (p value < .05) improved agitation and aggression in a sub-population of Alzheimer's disease patients with severe agitation and aggression In this popul |
|
| September 15, 2015 |
MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL STATEMENTS Exhibit 99.3 MANAGEMENT?S RESPONSIBILITY FOR FINANCIAL STATEMENTS The accompanying consolidated financial statements of Transition Therapeutics Inc. have been prepared by management and have been approved by the Board of Directors. Management is responsible for the information and representation contained in these consolidated financial statements. The consolidated financial statements have been p |
|
| September 15, 2015 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify that: 1. Review: I have reviewed the AIF, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the ?annual filings?) of Transitio |
|
| September 15, 2015 |
Exhibit 99.6 To Our Shareholders: The focus of fiscal 2015 was on the clinical development of our lead drug candidates. Our Irish subsidiary, Transition Therapeutics Ireland Limited (TTIL), focused its efforts on the development of neuropsychiatric drug candidate, ELND005. Transition?s other development subsidiary, Waratah Pharmaceuticals Inc., supported the clinical development of lead diabetes c |
|
| September 15, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by ch |
|
| September 15, 2015 |
Transition Therapeutics Announces Fiscal 2015 Financial Results Exhibit 99.7 Transition Therapeutics Announces Fiscal 2015 Financial Results TORONTO, ON, September 15, 2015 ? Transition Therapeutics Inc. (?Transition? or the ?Company?) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the year ended June 30, 2015. Investors are invi |
|
| September 15, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS The following is a discussion and analysis of the operating results and financial position of Transition Therapeutics Inc. for the year ended June 30, 2015. This document should be read in conjunction with the Company?s audited consolidated financial statements and the accompanying notes, which have been prepared in accordance with International Fi |
|
| September 15, 2015 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the ?annual filings?) of Tra |
|
| September 15, 2015 |
Exhibit 99.1 TRANSITION THERAPEUTICS INC. ANNUAL INFORMATION FORM For the year ended June 30, 2015 September 14, 2015 TABLE OF CONTENTS PRELIMINARY 1 CAUTION REGARDING FORWARD-LOOKING STATEMENTS 1 CORPORATE STRUCTURE 2 Name, Address and Incorporation 2 Intercorporate Relationships 3 GENERAL DEVELOPMENT OF THE BUSINESS 3 Three Year History 3 Trends 7 BUSINESS OF THE CORPORATION 7 General 7 Technolo |
|
| September 15, 2015 |
Transition Therapeutics FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F [Mark One] ? REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2015 Commission File Number: 001-33514 TRANSITION THERAPEUTICS INC. (Exact name of Registra |
|
| September 14, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by ch |
|
| September 14, 2015 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Fiscal 2015 Financial Results on Tuesday, September 15th, at 4:30 P.M. EST TORONTO, Sept. 14, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, September 15th, 2015 at 4:30 P.M. EST to discuss full year Fiscal 2015 financial results. Dr. Tony Cruz |
|
| August 10, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| August 10, 2015 |
Transition Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference Exhibit 99.1 Transition Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference TORONTO, Aug. 10, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Canaccord Genuity 35th Annual Growth Conference on Thursday, August |
|
| June 24, 2015 |
Exhibit 99.1 Transition Therapeutics Announces Results of Clinical Study of ELND005 in Agitation and Aggression in Patients with Alzheimer's Disease TORONTO, June 24, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that a Phase 2/3 clinical study of neuropsychiatric drug candidate ELND005 did not meet its primary efficacy endpoint. In th |
|
| June 24, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| June 16, 2015 |
Transition Therapeutics Appoints Carl Damiani as President Exhibit 99.1 Transition Therapeutics Appoints Carl Damiani as President TORONTO, June 16, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce the appointment of Carl Damiani as President and Chief Operating Officer of Transition. "Carl has worked closely with me over many years |
|
| June 16, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| May 26, 2015 |
Transition Therapeutics to Present at the Jefferies 2015 Healthcare Conference Exhibit 99.1 Transition Therapeutics to Present at the Jefferies 2015 Healthcare Conference TORONTO, May 26, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Jefferies 2015 Healthcare Conference on Tuesday, June 2 at 4:00pm Eastern time |
|
| May 26, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 12, 2015 |
Transition Therapeutics Announces Third Quarter Fiscal 2015 Financial Results Exhibit 99.1 Transition Therapeutics Announces Third Quarter Fiscal 2015 Financial Results TORONTO, ON, May 12, 2015 ? Transition Therapeutics Inc. (?Transition? or the ?Company?) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three and nine month periods ended M |
|
| May 12, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company?s unaudited consolidated financial statements for the nine and three month periods ended March 31, 2015 and the related notes, which are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board for interi |
|
| May 12, 2015 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Transition Therapeutics Inc. (the ?issuer?) for the interim period ended March 31, 2015. 2. No misrepresentations: Base |
|
| May 12, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 12, 2015 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Transition Therapeutics Inc. (the ?issuer?) for the interim period ended March 31, 2015. 2. No misrepresentations: B |
|
| May 12, 2015 |
EX-99.6 7 v410180ex99-6.htm LETTER TO SHAREHOLDERS Exhibit 99.6 To Our Shareholders The third quarter marks an important milestone in the advancement of lead neuropsychiatric drug candidate, ELND005, and lead diabetes drug candidate, TT401 (LY2944876), with each completing enrolment of a large Phase 2 clinical study. For ELND005, 350 Alzheimer’s disease (“AD”) patients with moderate to severe leve |
|
| May 12, 2015 |
Exhibit 99.3 Consolidated Interim Financial Statements (Unaudited) Transition Therapeutics Inc. For the nine and three months ended March 31, 2015 and 2014 1 Transition Therapeutics Inc. CONSOLIDATED BALANCE SHEETS (Unaudited) In Canadian Dollars Note As at March 31, 2015 As at June 30, 2014 Assets Current assets Cash 50,248,469 57,212,004 Short term investments 6 - 3,059,562 Other receivables 1,3 |
|
| May 11, 2015 |
Exhibit 99.1 LICENSE AGREEMENT by and among TRANSITION THERAPEUTICS IRELAND LIMITED and ELI LILLY and COMPANY LICENSE AGREEMENT This Agreement (the ?Agreement?), effective as of May 5, 2015 (the ?Effective Date?), is entered into by and among Transition Therapeutics Ireland Limited, an Irish company with its registered office at Arthur Cox Building, Earlsfort Terrace, Dublin 2 Ireland (hereinafter |
|
| May 11, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 8, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 8, 2015 |
EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 7, 2015 Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2015 Financial Results on Tuesday, May 12th, at 4:30 P.M. EST TORONTO, May 7, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, May 12th, 2015 at 4:30 P.M. EST to discuss Thir |
|
| May 6, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 6, 2015 |
Transition Therapeutics In-Licenses Phase 2 Drug Candidate from Lilly Exhibit 99.1 Transition Therapeutics In-Licenses Phase 2 Drug Candidate from Lilly TORONTO, May 6, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited ("TTIL"), has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly |
|
| March 27, 2015 |
Exhibit 99.1 Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of Neuropsychiatric Drug Candidate ELND005 TORONTO, March 26, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX:TTH) today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-me |
|
| March 27, 2015 |
Transition Therapeutics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| March 2, 2015 |
Exhibit 99.1 Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease TORONTO, March 2, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited ("TTIL") completed enrolment of |
|
| March 2, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| February 19, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 19, 2015 |
Transition Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference Exhibit 99.1 Transition Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference TORONTO, Feb. 19, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Cowen and Company 35th Annual Healthcare Conference on Monday, |
|
| February 18, 2015 |
Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares Exhibit 99.1 Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares TORONTO, ON, February 18, 2015 – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) today announced the closing of its underwritten public offering of an aggregate of 3,538,461 common shares at a price to the public of US$6.50 per share, including 461, |
|
| February 18, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 v4021456k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Exec |
|
| February 17, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 v4020066k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Exec |
|
| February 12, 2015 |
Filed pursuant to Rule 424(b)(5) Registration Statement Number 333-189879 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 19, 2013) 3,076,923 Shares Common Shares We are offering 3,076,923 of our common shares pursuant to this prospectus supplement and accompanying prospectus. |
|
| February 12, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 12, 2015 |
Transition Therapeutics Inc. Announces Public Offering of Common Shares Exhibit 99.1 Transition Therapeutics Inc. Announces Public Offering of Common Shares TORONTO, ON, February 11, 2015 – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) announced today that it has commenced an underwritten public offering of its common shares. The Company expects to use net proceeds from the sale of the common shares for general corporate purpose |
|
| February 12, 2015 |
3,076,923 Shares TRANSITION THERAPEUTICS INC. Common Shares UNDERWRITING AGREEMENT Exhibit 1.1 3,076,923 Shares TRANSITION THERAPEUTICS INC. Common Shares UNDERWRITING AGREEMENT February 11, 2015 Cowen and Company, LLC As Representative of the several Underwriters named in Schedule A hereto 599 Lexington Avenue New York, New York 10022 Dear Sirs: 1. Introductory. Transition Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company |
|
| February 12, 2015 |
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares Exhibit 99.2 Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares TORONTO, ON, February 12, 2015 – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) today announced the pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of US$ |
|
| February 11, 2015 |
Transition Therapeutics Inc. Announces Public Offering of Common Shares EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 11, 2015 Exhibit 99.1 Transition Therapeutics Inc. Announces Public Offering of Common Shares TORONTO, Feb. 11, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that it has commenced an underwritten public offering of its common shares. The Company expects to use net proceeds from the |
|
| February 11, 2015 |
Filed pursuant to Rule 424(b)(5) Registration Statement Number 333-189879 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 11, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 9, 2015 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE EX-99.5 6 v400635ex99-5.htm CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF FINANCIAL OFFICER Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therap |
|
| February 9, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS EX-99.2 3 v400635ex99-2.htm MANAGEMENT'S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company’s unaudited consolidated financial statements for the three and six month periods ended December 31, 2014 and the related notes, which are prepared in accordance with International Financial Reporting Standards a |
|
| February 9, 2015 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeutics Inc. (the “issuer”) for the interim period ended December 31, 2014. 2. No misrepresentations: B |
|
| February 9, 2015 |
EX-99.6 7 v400635ex99-6.htm LETTER TO SHAREHOLDERS Exhibit 99.6 To Our Shareholders The second quarter of fiscal 2015 is highlighted by continued progress toward the completion of enrolment for our Phase 2 studies of both neuropsychiatric drug candidate ELND005 and diabetes drug candidate TT401 (LY2944876). During the quarter, there were also multiple ELND005 presentations of data from the study i |
|
| February 9, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 v4006356k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Exec |
|
| February 9, 2015 |
Consolidated Interim Financial Statements Exhibit 99.3 Consolidated Interim Financial Statements (Unaudited) Transition Therapeutics Inc. For the three and six months ended December 31, 2014 and 2013 1 Transition Therapeutics Inc. CONSOLIDATED BALANCE SHEETS (Unaudited) In Canadian Dollars Note As at December 31, 2014 As at June 30, 2014 Assets Current assets Cash 26,756,324 57,212,004 Short term investments 6 - 3,059,562 Other receivable |
|
| February 9, 2015 |
Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results Exhibit 99.1 Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results TORONTO, ON, February 9, 2015 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three and six month periods end |
|
| February 5, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 5, 2015 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2015 Financial Results on Monday, February 9th, at 4:30 P.M. EST TORONTO, Feb. 5, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Monday, February 9th, 2015 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2015 financial results. D |
|
| January 30, 2015 |
TTHI / Transition Therapeutics Inc. / FEINBERG LARRY N - AMENDMENT NO. 8 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 8) Under the Securities Exchange Act of 1934 Transition Therapeutics, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 893716209 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 6, 2015 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2015 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by chec |
|
| January 6, 2015 |
Exhibit 1.1 TRANSITION THERAPEUTICS INC. COMMON shares Having an aggregate offering price of up to US$25 million SALES AGREEMENT January 5, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Transition Therapeutics Inc., a corporation organized under the laws of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, |
|
| January 6, 2015 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-189879 PROSPECTUS SUPPLEMENT (To Prospectus dated July 19, 2013) $25,000,000 Common Shares We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to the sale of our common shares, no par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sal |
|
| December 10, 2014 |
Exhibit 99.1 |
|
| December 10, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| December 8, 2014 |
Transition Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference Exhibit 99.1 Transition Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference TORONTO, Dec. 8, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 1 |
|
| December 8, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 24, 2014 |
Transition Therapeutics' ELND005 Showed No Prolongation of QT Interval Exhibit 99.1 Transition Therapeutics' ELND005 Showed No Prolongation of QT Interval TORONTO, Nov. 24, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX:TTH) today announced results from a thorough QT (tQT) study in which no QT effects were observed at supra-therapeutic single doses of neuropsychiatric drug candidate, ELND005. A tQT study is a specialized |
|
| November 24, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 transitionthera6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Princi |
|
| November 20, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 20, 2014 |
Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome Exhibit 99.1 Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome TORONTO, Nov. 20, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the results of a clinical study of neuropsychiatric drug candidate ELND005 in young adults with Down syndrome. Transition's wholly-owned subsidiary, Transi |
|
| November 14, 2014 |
TRANSITION THERAPEUTICS INC. Annual Meeting of Shareholders Management Information Circular Exhibit 99.1 TRANSITION THERAPEUTICS INC. Annual Meeting of Shareholders Management Information Circular This Management Information Circular (“Circular”) is furnished in connection with the solicitation of proxies by and on behalf of the management of Transition Therapeutics Inc. (the “Corporation”) for use at the Annual Meeting of the Corporation’s shareholders to be held on December 9, 2014 at |
|
| November 14, 2014 |
Exhibit 99.2 |
|
| November 14, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 12, 2014 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company’s unaudited consolidated financial statements for the three-month period ended September 30, 2014 and the related notes, which are prepared in accordance with International Financial Reporting Standards for interim financial statements, including IAS 34, Interim Reporting (IFR |
|
| November 12, 2014 |
Consolidated Interim Financial Statements Exhibit 99.3 Consolidated Interim Financial Statements (Unaudited) Transition Therapeutics Inc. For the three months ended September 30, 2014 and 2013 1 Transition Therapeutics Inc. CONSOLIDATED BALANCE SHEETS (Unaudited) In Canadian Dollars Note As at September 30, 2014 As at June 30, 2014 Assets Current assets Cash 42,782,040 57,212,004 Short term investments 6 3,073,551 3,059,562 Other receivab |
|
| November 12, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 12, 2014 |
Exhibit 99.6 To our shareholders The first quarter of fiscal 2015 is highlighted by the continued advancement of lead neuropsychiatric drug candidate ELND005 and diabetes drug candidate TT401 (LY2944876). Our wholly owned subsidiary, Transition Therapeutics Ireland Limited (“TTIL”) has been focused on the execution of the ELND005 Phase 2 study of agitation and aggression in Alzheimer’s disease (AD |
|
| November 12, 2014 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeutics Inc. (the “issuer”) for the interim period ended September 30, 2014. 2. No misrepresentations: |
|
| November 12, 2014 |
Transition Therapeutics Announces First Quarter Fiscal 2015 Financial Results Exhibit 99.1 Transition Therapeutics Announces First Quarter Fiscal 2015 Financial Results TORONTO, ON, November 12, 2014 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three month period ended Septem |
|
| November 12, 2014 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeutics Inc. (the “issuer”) for the interim period ended September 30, 2014. 2. No misrepresentation |
|
| November 10, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 10, 2014 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2015 Financial Results on Wednesday, November 12th, at 4:30 P.M. EST TORONTO, Nov. 10, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, November 12th, 2014 at 4:30 P.M. EST to discuss First Quarter Fiscal 2015 financial res |
|
| November 4, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 4, 2014 |
Transition Therapeutics Reports Findings from Bipolar Disorder Phase 2 Study Exhibit 99.1 Transition Therapeutics Reports Findings from Bipolar Disorder Phase 2 Study TORONTO, Nov. 4, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD). Transition's wholly- |
|
| September 25, 2014 |
Exhibit 99.4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 13a-14(a) I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify that: 1. I have reviewed this annual report on Form 40-F of Transition Therapeutics Inc. (the issuer) for the year ended June 30, 2014; 2. Based on my knowledge, this report does not contain any untrue sta |
|
| September 25, 2014 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 99.6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, in connection with the Company’s Annual Report as filed on Form 40-F for the fiscal year ending |
|
| September 25, 2014 |
Transition Therapeutics Announces Fiscal 2014 Year End Financial Results Exhibit 99.1 Transition Therapeutics Announces Fiscal 2014 Year End Financial Results TORONTO, ON, September 25, 2014 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the year ended June 30, 2014. Selected |
|
| September 25, 2014 |
TTHI / Transition Therapeutics Inc. 40-F - - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 40-F [Check one] ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2014 Commission File Number: 001-33514 TRANSITION THERAPEUTICS INC. (Exact name of Registr |
|
| September 25, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by ch |
|
| September 25, 2014 |
Consent of Independent Auditor Exhibit 99.8 Consent of Independent Auditor We hereby consent to the incorporation by reference in this Annual Report on Form 40-F for the year ended June 30, 2014 of Transition Therapeutics Inc. of our report dated September 19, 2014, relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which appears in the Exhibit incorporated by r |
|
| September 25, 2014 |
MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL STATEMENTS Exhibit 99.3 MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL STATEMENTS The accompanying consolidated financial statements of Transition Therapeutics Inc. have been prepared by management and have been approved by the Board of Directors. Management is responsible for the information and representation contained in these consolidated financial statements. The consolidated financial statements have been p |
|
| September 25, 2014 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 99.7 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, in connection with the Company’s Annual Report as filed on Form 40-F for the fiscal year end |
|
| September 25, 2014 |
Exhibit 99.1 TRANSITION THERAPEUTICS INC. ANNUAL INFORMATION FORM For the year ended June 30, 2014 September 19, 2014 TABLE OF CONTENTS PRELIMINARY 1 CAUTION REGARDING FORWARD-LOOKING STATEMENTS 1 CORPORATE STRUCTURE 2 Name, Address and Incorporation 2 Intercorporate Relationships 3 GENERAL DEVELOPMENT OF THE BUSINESS 3 Three Year History 3 Recent Developments 7 Trends 7 BUSINESS OF THE CORPORATIO |
|
| September 25, 2014 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS The following is a discussion and analysis of the operating results and financial position of Transition Therapeutics Inc. for the year ended June 30, 2014. This document should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes, which have been prepared in accordance with International Fi |
|
| September 25, 2014 |
Exhibit 99.2 Dear Shareholders, It is with great enthusiasm that I report to you on our fiscal year 2014 which is highlighted by an important acquisition, advancement of our partnered diabetes asset, multiple private placement financings and activities to expand the core strategy of our business. The acquisition of the neuropsychiatric drug candidate, ELND005, from Perrigo Company plc (“Perrigo”) |
|
| September 25, 2014 |
Exhibit 99.5 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 13a-14(a) I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify that: 1. I have reviewed this annual report on Form 40-F of Transition Therapeutics Inc. (the issuer) for the year ended June 30, 2014; 2. Based on my knowledge, this report does not contain any untrue |
|
| September 22, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 transitionthera6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Princ |
|
| September 22, 2014 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2014 Financial Results on Thursday, September 25th, at 4:30 P.M. EST TORONTO, Sept. 22, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Thursday, September 25th, 2014 at 4:30 P.M. EST to discuss Full Year Fiscal 2014 financial results. D |
|
| July 11, 2014 |
TTHI / Transition Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| July 11, 2014 |
Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer Exhibit 99.1 Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer TORONTO, July 11, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl Damiani has been appointed to the role of Chief Operating Officer of Transition. "This appointment reflects Mr. |
|
| July 2, 2014 |
EX-99.3 EXHIBIT 3 These Warrants shall not be exercisable by the holder, in whole or in part, and Transition Therapeutics Inc. (the Corporation) shall not give effect to any such exercise, if, after giving effect to such exercise, the holder, together with any person or company acting jointly or in concert with the holder (the Joint Actors) would in the aggregate beneficially own, or exercise cont |
|
| July 2, 2014 |
SUBSCRIPTION AGREEMENT FOR UNITS EX-99.2 EXHIBIT 2 UNITED STATES SUBSCRIPTION AGREEMENT FOR UNITS INSTRUCTIONS: To properly complete this Subscription Agreement: (1) All subscribers must complete all boxes on this face page. (2) All subscribers must complete and sign Exhibit 1 and Exhibit 2. (3) All subscribers should return their completed documents by email or fax to the Corporation at [email protected] or 416-2 |
|
| July 2, 2014 |
EX-99.1 EXHIBIT 1 Joint Filing Agreement This Joint Filing Agreement is entered into as of July 1, 2014, by the undersigned, who hereby agree that the Statement on Amendment No. 2 to Schedule 13D in respect of the common shares ofTransition Therapeutics Inc. is, and any amendment subsequently signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in |
|
| July 2, 2014 |
SCHEDULE 13D AMENDMENT NO. 2 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information To Be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* TRANSITION THERAPEUTICS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 893 |
|
| June 26, 2014 |
Transition Therapeutics Announces Closing of Private Placement Equity Financing Exhibit 99.1 Transition Therapeutics Announces Closing of Private Placement Equity Financing TORONTO, June 23, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced that it has closed its previously announced private placement through which 3,195,487 units of the Company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment |
|
| June 26, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| June 6, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check m |
|
| June 6, 2014 |
Exhibit 99.1 Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$30.8 Million in Equity Financing Company to Receive Upfront US$17 Million Upon Closing TORONTO, June 6, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Tran |
|
| May 27, 2014 |
Transition Therapeutics to Host Investor Day and Webcast on May 28th in New York City Exhibit 99.1 Transition Therapeutics to Host Investor Day and Webcast on May 28th in New York City Live Webcast Beginning at 8am Eastern Time on May 28th TORONTO, May 27, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced today that it will host an Investor Day on Wednesday, May 28th in New York City. An industry key opinion leader, Consta |
|
| May 27, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 23, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 23, 2014 |
Transition Therapeutics to Present at Jefferies 2014 Global Healthcare Conference Exhibit 99.1 Transition Therapeutics to Present at Jefferies 2014 Global Healthcare Conference TORONTO, May 22, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Jefferies 2014 Global Healthcare Conference on Monday, June 2nd, at 8:30 a.m |
|
| May 15, 2014 |
Transition Therapeutics Diabetes Drug Candidate, TT-401, Commences Phase 2 Clinical Study Exhibit 99.1 Transition Therapeutics Diabetes Drug Candidate, TT-401, Commences Phase 2 Clinical Study TORONTO, May 15, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes. The study is expected to en |
|
| May 15, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 13, 2014 |
Consolidated Interim Financial Statements Exhibit 99.3 Consolidated Interim Financial Statements (Unaudited) Transition Therapeutics Inc. For the nine and three month periods ended March 31, 2014 and 2013 1 CONSOLIDATED BALANCE SHEETS (Unaudited) As at In Canadian Dollars Note March 31, 2014 June 30, 2013 Assets Current assets Cash 48,834,630 23,067,937 Short term investments 7 4,063,819 5,057,702 Other receivables 33,366 35,792 Investmen |
|
| May 13, 2014 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| May 13, 2014 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE EX-99.4 5 v378191ex99-4.htm CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF EXECUTIVE OFFICER Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeut |
|
| May 13, 2014 |
MANAGEMENT’S DISCUSSION AND ANALYSIS EX-99.2 3 v378191ex99-2.htm MANAGEMENTS DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company’s unaudited consolidated financial statements for the three and nine month periods ended March 31, 2014 and the related notes, which are prepared in accordance with International Financial Reporting Standards (IFR |
|
| May 13, 2014 |
EX-99.6 7 v378191ex99-6.htm LETTER TO SHAREHOLDERS Exhibit 99.6 To Our Shareholders The third quarter of fiscal 2014 is highlighted by the Company’s acquisition of the development and commercialization rights to neuropsychiatric drug candidate, ELND005. This transaction broadened the Company’s development pipeline with an un-partnered late-stage clinical asset, coupled with Transition’s core strat |
|
| May 13, 2014 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE EX-99.5 6 v378191ex99-5.htm CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF FINANCIAL OFFICER Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therap |
|
| May 13, 2014 |
Transition Therapeutics Announces Third Quarter Fiscal 2014 Financial Results EX-99.1 2 v378191ex99-1.htm PRESS RELEASE DATED MAY 13, 2014 Exhibit 99.1 FOR IMMEDIATE RELEASE Transition Therapeutics Announces Third Quarter Fiscal 2014 Financial Results TORONTO, ON, May 13, 2014 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, |
|
| May 12, 2014 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2014 Financial Results on Tuesday, May 13th, at 4:30 P.M. EST TORONTO, May 12, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, May 13th, 2014 at 4:30 P.M. EST to discuss Third Quarter Fiscal 2014 financial results. Dr. Tony |
|
| May 12, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check ma |
|
| April 16, 2014 |
Transition Therapeutics Announces No Material Change Exhibit 99.1 Transition Therapeutics Announces No Material Change TORONTO, April 15, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) reports today that there are no undisclosed material changes or corporate developments involving the Company to account for its recent change in stock price. About Transition Transition is a biopharmaceutical company |
|
| April 16, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| April 7, 2014 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 transitionthera6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal |
|
| April 7, 2014 |
Transition Therapeutics Announces Development Update Exhibit 99.1 Transition Therapeutics Announces Development Update TORONTO, April 7, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) provided an update on the development of its drug candidates and plans for future growth. The addition of the neuropsychiatric drug candidate ELND005 has broadened the Company's development pipeline with an un-partne |
|
| March 7, 2014 |
TTHI / Transition Therapeutics Inc. / PERRIGO Co plc - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Transition Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 893716209 (CUSIP Number) February 28, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| March 3, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by check |
|
| March 3, 2014 |
Exhibit 99.1 Perrigo Company plc and Transition Therapeutics Modify Development and Commercialization Rights of ELND005 Program · All development and commercialization rights of ELND005 drug candidate have been transferred to an Irish-domiciled company ("Irish Subsidiary") · Transition has acquired 100% of the common shares of Irish Subsidiary · Irish Subsidiary will be responsible for the future |
|
| March 3, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| March 3, 2014 |
Transition Therapeutics to Present at the 34th Annual Cowen & Co. Healthcare Conference Exhibit 99.1 Transition Therapeutics to Present at the 34th Annual Cowen & Co. Healthcare Conference TORONTO, March 3, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 34th Annual Cowen & Co. Healthcare Conference on Tuesday, March 4th, |
|
| February 18, 2014 |
February 18, 2014 Mr. Jeffrey Riedler United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. E. Washington, D.C. 20549 Re: Transition Therapeutics Inc. Form 20-F for the Fiscal Year Ended June 30, 2013 Filed September 11, 2013 File No. 001-33514 Dear Mr. Riedler: We are writing in response to your comment letter dated February 12, 2014 relating to Transit |
|
| February 12, 2014 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company’s unaudited consolidated financial statements for the three and six month periods ended December 31, 2013 and the related notes, which are prepared in accordance with International Financial Reporting Standards (IFRS) for interim financial statements, as well as the audited co |
|
| February 12, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2014 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 12, 2014 |
Transition Therapeutics Announces Second Quarter Fiscal 2014 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Transition Therapeutics Announces Second Quarter Fiscal 2014 Financial Results TORONTO, ON, February 12, 2014 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three an |
|
| February 12, 2014 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeutics Inc. (the “issuer”) for the interim period ended December 31, 2013. 2. No misrepresentations |
|
| February 12, 2014 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeutics Inc. (the “issuer”) for the interim period ended December 31, 2013. 2. No misrepresentations: B |
|
| February 12, 2014 |
Consolidated Interim Financial Statements Exhibit 99.3 Consolidated Interim Financial Statements (Unaudited) Transition Therapeutics Inc. For the six and three month periods ended December 31, 2013 and 2012 1 CONSOLIDATED BALANCE SHEETS (Unaudited) As at In Canadian Dollars Note December 31, 2013 June 30, 2013 Assets Current assets Cash and cash equivalents 32,341,634 23,067,937 Short term investments 6 4,045,573 5,057,702 Other receivabl |
|
| February 12, 2014 |
Exhibit 99.6 To Our Shareholders This fiscal quarter is highlighted by advancement of our multiple programs in development. The two large Phase 2 studies of our lead neuropsychiatric drug candidate, ELND005, in bipolar disorder and agitation and aggression associated with Alzheimer’s disease are continuing to progress toward completion. Our lead metabolic drug candidate, TT401, is in preparation f |
|
| February 7, 2014 |
Exhibit 99.1 Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2014 Financial Results on Wednesday, February 12th, at 4:30 P.M. EST TORONTO, Feb. 7, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, February 12th, 2014 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2014 financial re |
|
| February 7, 2014 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2013 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| February 7, 2014 |
TTHI / Transition Therapeutics Inc. / FEINBERG LARRY N - SC 13G/A Passive Investment SC 13G/A 1 v367681sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 7) Under the Securities Exchange Act of 1934 Transition Therapeutics, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 893716209 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| December 16, 2013 |
Exhibit 99.1 TRANSITION THERAPEUTICS INC ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON DECEMBER 13, 2013 FINAL SCRUTINEERS' REPORT 0 SHAREHOLDERS IN PERSON, REPRESENTING 0 SHARES 73 SHAREHOLDERS BY PROXY, REPRESENTING 24,820,638 SHARES 73 TOTAL SHAREHOLDERS, HOLDING 24,820,638 SHARES TOTAL ISSUED AND OUTSTANDING AS AT RECORD DATE: 29,619,456 PERCENTAGE OF OUTSTANDING SHARES REPRESENTED AT THE MEE |
|
| December 16, 2013 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2013 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 21, 2013 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2013 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 21, 2013 |
Exhibit 99.2 |
|
| November 21, 2013 |
TRANSITION THERAPEUTICS INC. Annual Meeting of Shareholders Management Information Circular Exhibit 99.1 TRANSITION THERAPEUTICS INC. Annual Meeting of Shareholders Management Information Circular This Management Information Circular (“Circular”) is furnished in connection with the solicitation of proxies by and on behalf of the management of Transition Therapeutics Inc. (the “Corporation”) for use at the Annual Meeting of the Corporation’s shareholders to be held on December 13, 2013 at |
|
| November 18, 2013 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Transition Therapeutics Announces ELND005 Presentations at the Clinical Trials in Alzheimer’s Disease (CTAD) Meeting TORONTO, ON, November 18th, 2013 – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) announced ELND005 (scyllo-inositol) was featured in an oral and two poster presentations at the recently completed 6th Annual C |
|
| November 18, 2013 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2013 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 12, 2013 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2013 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by che |
|
| November 12, 2013 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.5 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeutics Inc. (the “issuer”) for the interim period ended September 30, 2013. 2. No misrepresentation |
|
| November 12, 2013 |
Transition Therapeutics Announces First Quarter Fiscal 2014 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Transition Therapeutics Announces First Quarter Fiscal 2014 Financial Results TORONTO, ON, November 12, 2013 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three mon |
|
| November 12, 2013 |
Exhibit 99.6 To Our Shareholders This fiscal quarter was highlighted by important milestones in the advancement of our development candidates and the addition of a new program through a collaboration with Lilly. Our lead neuropsychiatric drug candidate, ELND005, received FDA “Fast Track” designation for the treatment of agitation and aggression in Alzheimer’s disease and an additional Phase 2A stu |
|
| November 12, 2013 |
Consolidated Interim Financial Statements Exhibit 99.3 Consolidated Interim Financial Statements (Unaudited) Transition Therapeutics Inc. For the three months ended September 30, 2013 and 2012 1 Transition Therapeutics Inc. CONSOLIDATED BALANCE SHEETS (Unaudited) In Canadian Dollars Note As at September 30, 2013 As at June 30, 2013 Assets Current assets Cash and cash equivalents 32,173,444 23,067,937 Short term investments 6 5,080,203 5,0 |
|
| November 12, 2013 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS The following information should be read in conjunction with the Company’s unaudited consolidated financial statements for the three-month period ended September 30, 2013 and the related notes, which are prepared in accordance with International Financial Reporting Standards (IFRS) for interim financial statements, as well as the audited consolidat |
|
| November 12, 2013 |
Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE Exhibit 99.4 Form 52-109F2 Certification of Interim Filings FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Transition Therapeutics Inc. (the “issuer”) for the interim period ended September 30, 2013. 2. No misrepresentations: |
|
| September 11, 2013 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2013 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by ch |
|
| September 11, 2013 |
SUBSCRIPTION AGREEMENT FOR UNITS Exhibit 4.11 UNITED STATES SUBSCRIPTION AGREEMENT FOR UNITS INSTRUCTIONS: To properly complete this Subscription Agreement: (1) All subscribers must complete all boxes on this face page. (2) All subscribers must complete and sign Exhibit 1 and Exhibit 2. (3) All subscribers should return their completed documents by email or fax to the Corporation at [email protected] or 416-260-28 |
|
| September 11, 2013 |
Transition Therapeutics Announces Fiscal 2013 Year End Financial Results Exhibit 99.7 Transition Therapeutics Announces Fiscal 2013 Year End Financial Results TORONTO, ON, September 11, 2013 – Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the year ended June 30, 2013. Selected |
|
| September 11, 2013 |
MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL STATEMENTS Exhibit 99.3 MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL STATEMENTS The accompanying consolidated financial statements of Transition Therapeutics Inc. have been prepared by management and have been approved by the Board of Directors. Management is responsible for the information and representation contained in these consolidated financial statements. The consolidated financial statements have been p |
|
| September 11, 2013 |
Exhibit 2.2 THESE WARRANTS WILL BE VOID AND OF NO VALUE UNLESS EXERCISED BEFORE TIME OF EXPIRY (AS DEFINED HEREIN). Unless permitted under securities legislation, the holder of this security must not trade the security before [DECEMBER ·], 2013. THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") OR ANY S |
|
| September 11, 2013 |
Exhibit 2.1 THESE WARRANTS WILL BE VOID AND OF NO VALUE UNLESS EXERCISED BEFORE TIME OF EXPIRY (AS DEFINED HEREIN). Unless permitted under securities legislation, the holder of this security must not trade the security before [DECEMBER ·], 2013. THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") OR ANY S |
|
| September 11, 2013 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the “annual filings”) of Tra |
|
| September 11, 2013 |
Consent of Independent Auditor Exhibit 15.1 Consent of Independent Auditor We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-189879) and on Form S-8 (No. 333-157279) of Transition Therapeutics Inc. of our report dated September 6, 2013 relating to the consolidated financial statements, which appears as an Exhibit in this Form 20-F, which is incorporated in this Annual Report |
|
| September 11, 2013 |
Exhibit 99.1 TRANSITION THERAPEUTICS INC. ANNUAL INFORMATION FORM For the year ended June 30, 2013 September 6, 2013 TABLE OF CONTENTS PRELIMINARY 1 CAUTION REGARDING FORWARD-LOOKING STATEMENTS 1 CORPORATE STRUCTURE 2 Name, Address and Incorporation 2 Intercorporate Relationships 2 GENERAL DEVELOPMENT OF THE BUSINESS 3 Three Year History 3 Recent Developments 6 Trends 7 BUSINESS OF THE CORPORATION |
|
| September 11, 2013 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS The following is a discussion and analysis of the operating results and financial position of Transition Therapeutics Inc. for the year ended June 30, 2013. This document should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes, which have been prepared in accordance with International Fi |
|
| September 11, 2013 |
SUBSCRIPTION AGREEMENT FOR UNITS Exhibit 4.10 CANADA/OFFSHORE SUBSCRIPTION AGREEMENT FOR UNITS INSTRUCTIONS: To properly complete this Subscription Agreement: (1) All subscribers must complete all boxes on these two face pages. (2) All subscribers should return their completed documents by email or fax to the Corporation at [email protected] or 416-260-2886, Attention: N. Nicole Rusaw This Subscription Agreement i |
|
| September 11, 2013 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, in connection with the Company’s Annual Report as filed on Form 20-F for the fiscal year end |
|
| September 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F [Mark One] ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2013 Commission File Number: 001-33514 TRANSITION THERAPEUTICS INC. (Exact name of Registra |
|
| September 11, 2013 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify that: 1. Review: I have reviewed the AIF, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the “annual filings”) of Transitio |
|
| September 11, 2013 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, in connection with the Company’s Annual Report as filed on Form 20-F for the fiscal year ending |
|
| September 11, 2013 |
Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 13a-14(a) I, Tony Cruz, Chief Executive Officer of Transition Therapeutics Inc., certify that: 1. I have reviewed this annual report on Form 20-F of Transition Therapeutics Inc. (the “company” ) for the year ended June 30, 2013; 2. Based on my knowledge, this report does not contain any untrue |
|
| September 11, 2013 |
Exhibit 99.6 Dear Shareholders, The goal of every biotechnology company is to ultimately offer a product of medical benefit to patients. With that goal always firmly in mind, Transition’s strategy has been to (a) leverage our internal strengths, (b) partner to access expertise and infrastructure for later stage development, and (c) expand our development pipeline with new drug candidates. From the |
|
| September 11, 2013 |
Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 13a-14(a) I, Nicole Rusaw, Chief Financial Officer of Transition Therapeutics Inc., certify that: 1. I have reviewed this annual report on Form 20-F of Transition Therapeutics Inc. (the “company”) for the year ended June 30, 2013; 2. Based on my knowledge, this report does not contain any untr |
|
| September 4, 2013 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2013 Commission File No.: 001-33514 TRANSITION THERAPEUTICS INC. 101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7 (Address of Principal Executive Office) Indicate by ch |
